Solos Endoscopy

Solos Endoscopy and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013 PR Newswire BOSTON, Jan. 24, 2013 BOSTON, Jan. 24, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 1 ISO 13485 Audit for February 26, 2013. Solos Endoscopy retained TUV SUD America, Inc. to complete its ISO 13485 Certification and Audit. The Company previously engaged Expert Resource to prepare the Company for the final audit, which will be conducted by TUV SUD America. TUV SUD Product Service is accredited by the ZLG in Bonn, Germany, as a Certification Body for quality management systems to the ISO 13485 standard. TUV SUD also holds accreditation with the Standards Council of Canada (SCC) and Health Canada for the Canadian Medical Devices Regulations. In addition, TUV SUD is a Notified Body for certification to all relevant EU Directives. With this complete service package, TUV SUD can assist medical companies in accessing markets nationally, in Europe, and globally. Solos Endoscopy has posted on its website an updated schedule as of January 2013. According to Solos Endoscopy, CEO, Robert Segersten, "Our team has been working diligently with Expert Resources and we believe that Solos will be prepared for the upcoming Audit in February." Expert Resource will attend the final audit, and help interpret any findings. Solos Endoscopy joins a high profile Expert Resource client list which includes BASF, Black & Decker, Dow Precision, Hitachi, J.D. Power & Associates, Microsoft Corporation, Northrop Grumman, Quest, and Toshiba, amongst many others. According to Expert Resource, their consultants maintain a 100% success rate of passing the final audit on the first attempt. Solos Endoscopy has posted its updated ISO 13485 CE Mark Schedule on its website, http://www.solosendoscopy.com/investors.html. About Solos Endoscopy, Inc.: Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. For more information on TUV SUD America visit www.tuvamerica.com. Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise. Investor Relations (617) 360-9719 SOURCE Solos Endoscopy, Inc. The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Moin Moin Auf zu ungeahnten Höhen würd ich mal ganz, gaaaanz kleinlaut herausschreien :) www.solosendoscopy.com/SNDY-ISO-13485-CE-Mark-Project-Schedule-July-2012.pdf so, das ist trotz atemberaubender News keine Kauf o. Verkaufsempfehlung - letztere schon mal gar nicht. so long.....

Grüß euch Leute,

Solos Endoscopy ISIN

US8343714031

könnte bzw wird meiner Meinung nach der Medical Stock Runner 2012.

Ich werde euch eine Zusammenfassung der Newslage hier darbieten.

 

Zuerst zur Sharestructure:

AS: 500.000.000

OS: ungefähr 440.000.000

 

News-Meldung: Am 02.03.2012

http://ih.advfn.com/p.php?pid=nmona&article=51461536

News-Meldung am 16.03.2012

http://ih.advfn.com/p.php?pid=nmona&article=51657021

Hier geht es um die Veröffentlichung eines neuen Instruments namens SteriTAP. Dieses Instrument dient zur Endoskopie Erklärung hierzu seht ihr

http://flexikon.doccheck.com/Endoskopie       <<<< hier.

Diese neue Linie SteriTAP soll auch demnächst die CE Mark erhalten. Diese wird benötigt, um die Endoskopie-Instrumenten in gewissen Ländern verkaufen zu dürfen, da gewisse Länder eine CE Mark voraussetzen.

Erklärung zu CE-Mark siehe

http://www.ce-marking.org/what-is-ce-marking.html       <<<< hier.

---------

Nun wollen wir uns noch einmal kurz den Chart ansehen. Hierbei habe ich eine representative Video-Chart-Analyse von Claytrader aus Investorhub.

Einigen von euch sollte dieser Name bestimmt etwas sagen.

 

Hierzu der Link zu seiner Videochart-Analyse auf der Basis von Freitags Schlusskurs

http://www.youtube.com/watch?v=z3JGynABJZc      <<<< hier!

Seiner Meinung nach sollte nach einem Kurs von 0,018 "Blue Sky Breakout" bevorstehen.

Wie stark SNDY ist konnten wir heute sehen, da sie nach früher Gewinnmitnahme in den ersten Stunden das Minus brach und deutlich ins Plus bis zu einem Tageshoch von 0,0235 gestiegen ist. Unser Schlusskurs hielt sich bei 0,0201.

Schaut es euch an und bildet euch eure Meinung - es ist es wert :)

 

LG dannyo